The US Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) plans revisions to its Investigational Device Exemption process to improve clinical trial management for manufacturers and sponsors, and may also consider down-classifying some devices from Class III Premarket Approval registration requirements. The CRDH’s plans were announced as part of the department’s 2014 Strategic Priorities, which also include “customer service” initiatives.